| Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. | |
| | |
MedLine Citation:
|
PMID: 18341664 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Impetigo is a common skin infection, primarily caused by Staphylococcus aureus and mainly occurring in children. It is usually treated topically with antibiotics to achieve a quick cure and prevent spread of the infection. Worldwide, resistance rates of S. aureus against commonly used antibiotics are rising. Retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections. OBJECTIVES: Our aim was to compare the efficacy and safety of topical application of retapamulin ointment with topical placebo ointment in the treatment of primary impetigo. METHODS: In a randomized, double-blind, multicentre study, patients received either topical retapamulin ointment 1% twice daily for 5 days or topical placebo. Patients were enrolled into the study for 14 days and attended the clinic for three visits during which clinical and laboratory evaluations were performed. RESULTS: Two hundred and thirteen patients were randomized, with 139 evaluable patients in the retapamulin group and 71 in the placebo group. Based on the primary efficacy endpoint of clinical response after 7 days (intention to treat), retapamulin ointment was superior to placebo (success rate 85.6% vs. 52.1%; P<0.0001). Similar results were found in the per protocol analysis and in the subgroup of patients who had a pathogen isolated at baseline. The most common adverse effect, pruritus at the application site, was reported by 6% and 1% of patients in the retapamulin and placebo groups, respectively. CONCLUSIONS: This study shows that topical retapamulin is effective and safe in the treatment of primary impetigo, offering a new treatment option. |
| | |
Authors:
|
S Koning; J C van der Wouden; O Chosidow; M Twynholm; K P Singh; N Scangarella; A P Oranje |
Related Documents
:
|
9167334 - Epidermal differentiation characteristics of the psoriatic plaque during short contact ... 3525264 - Response of solitary psoriatic plaques to experimental application of podophyllotoxin. 19634044 - Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% ... 22854344 - A long-term survivorship comparison between cemented and uncemented cups with shelf gra... 8825534 - Antiemetic effects of granisetron on postoperative nausea and vomiting in patients with... 10986994 - Functional comparison of posterior cruciate retention and substitution knee replacement. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2008-03-13 |
Journal Detail:
|
Title: The British journal of dermatology Volume: 158 ISSN: 0007-0963 ISO Abbreviation: Br. J. Dermatol. Publication Date: 2008 May |
Date Detail:
|
Created Date: 2008-04-14 Completed Date: 2008-08-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0004041 Medline TA: Br J Dermatol Country: England |
Other Details:
|
Languages: eng Pagination: 1077-82 Citation Subset: IM |
Affiliation:
|
Department of General Practice, Erasmus MC-University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Anti-Bacterial Agents / adverse effects, therapeutic use* Bicyclo Compounds, Heterocyclic / adverse effects, therapeutic use* Child Child, Preschool Double-Blind Method Female Humans Impetigo / drug therapy*, microbiology Infant Male Middle Aged Ointments Staphylococcus aureus |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 0/Bicyclo Compounds, Heterocyclic; 0/Ointments; 0/retapamulin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy...
Next Document: Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare pr...